Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Santiago De Compostela – page 57

690 clinical trials in Santiago De Compostela, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Santiago De Compostela at a glance
690
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

690 trials in Santiago De Compostela

Open in trial search

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Plasma cell myeloma

Not recruiting

Study of Belantamab Mafodotin, Carfilzomib, and Dexamethasone for Patients with Relapsed Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Fundacion PETHEMA

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Cervix carcinoma

Not recruiting

Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Patients Under 70 with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Fundacion PETHEMA

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Santiago De Compostela

What the registry says about research in the country

01 Respiratory Infections Research

Innovative studies focusing on respiratory viral infections, including trials for RSV, influenza, and COVID-19 vaccines. Research aims to enhance protection in vulnerable populations, particularly adults over 60.

  • RSV and hMPV vaccine development
  • Influenza vaccine efficacy studies
  • COVID-19 vaccine co-administration research

Multiple trials evaluating both single and combination vaccine approaches for respiratory diseases.

02 Cardiovascular Studies

Research targeting cardiovascular health and prevention, with emphasis on innovative treatments for stroke and heart failure. Studies include both therapeutic interventions and preventive measures.

  • Acute cerebral ischemic stroke treatment
  • Heart failure prevention strategies
  • Cardiovascular risk management

Focus on developing new therapeutic approaches for better patient outcomes.

03 Dermatological Research

Advanced clinical investigations in dermatological conditions, particularly focusing on moderate to severe cases of psoriasis and atopic dermatitis.

  • Plaque psoriasis treatments
  • Psoriatic arthritis therapies
  • Atopic dermatitis interventions

Trials evaluating novel therapeutic agents for chronic skin conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.